American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

The American Kidney Fund (AKF) is launching a comprehensive public health initiative on March 1, 2026, aimed at increasing awareness of kidney disease, which affects approximately 1 in 7 American adults. The campaign, titled "Kidneys Count," focuses on promoting early detection and prevention strategies through direct engagement with the public and healthcare providers. The initiative encourages Americans to prioritize kidney health discussions with their medical practitioners and to understand their individual risk factors.

As part of the broader campaign, the AKF will host Kidney Action Week from March 2-5, 2026, featuring a series of expert-led sessions dedicated to kidney disease management and treatment options. These educational events are designed to provide evidence-based information to both patients and caregivers seeking to understand disease progression and available medical interventions.

The timing of the campaign reflects growing concerns about chronic kidney disease prevalence in the United States. By emphasizing preventive measures and early medical intervention, the AKF aims to address the significant public health burden associated with undiagnosed or late-stage kidney disease, which can lead to substantial healthcare costs and complications if left untreated.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.

ARGX
The Motley Fool

Amgen and Merck Emerge as Defensive Dividend Plays Amid Economic Uncertainty

Amgen and Merck offer 3% dividend yields while successfully managing patent cliffs through diversified pipelines and new product approvals.

AMGNMRK
GlobeNewswire Inc.

Accumulus Launches Veeva RIM Integration, Streamlining Regulatory Submissions for Life Sciences

Accumulus launches Veeva RIM integration enabling real-time regulatory submissions. Amgen early adopter reports significant time savings and operational improvements.

AMGNVEEV
GlobeNewswire Inc.

Accumulus Technologies Launches Direct Connect for Veeva RIM, Streamlining Regulatory Submissions

Accumulus Technologies unveiled Direct Connect for Veeva RIM, enabling real-time integration between regulatory systems and health authorities, reducing manual work for life sciences companies.

AMGNVEEV
GlobeNewswire Inc.

Novartis Expands Radioligand Therapy Network with Texas Facility Groundbreaking

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.

NVS
GlobeNewswire Inc.

Novartis Expands RLT Empire: Texas Facility Part of $23B US Manufacturing Push

Novartis broke ground on a Texas radioligand therapy facility, the fifth in its US network, part of a $23 billion manufacturing investment expected operational by 2028.

NVS